StockData
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. (PCRX) stock

PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3028% above fair value
$36.48+0.00 (0.00%)

Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –

Earnings

Pacira BioSciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 5, 2026
Q3 FY2026 · estimated, after the close
Revenue, Q2 FY2026
$192.40M
+6.2% on a year earlier
Non-GAAP diluted net income per common share, Q2 FY2026
$0.73
$0.74 a year earlier
Latest guidance
Raised
Aug 4, 2026 · 9 items

Quarterly results

Revenue and earnings per share from each of Pacira BioSciences's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q3 FY2026ended Sep 30, 2026Nov 5, 2026Expected–––––
Q2 FY2026ended Jun 30, 2026Aug 4, 2026after the close$192.40M+6.2%$0.12$0.73Release
Q1 FY2026ended Mar 31, 2026Apr 30, 2026after the close$177.40M+5.0%$0.07$0.60Release
Q4 FY2025ended Dec 31, 2025Feb 26, 2026after the close$196.90M+5.1%$0.04$0.57Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025after the close$179.50M+6.5%$0.12$0.70Release
Q2 FY2025ended Jun 30, 2025Aug 5, 2025after the close$181.10M+1.7%-$0.11$0.74Release
Q1 FY2025ended Mar 31, 2025May 8, 2025after the close$168.90M+1.1%$0.10$0.62Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025after the close$187.30M+3.4%$0.34$0.91Release
Q3 FY2024ended Sep 30, 2024Nov 6, 2024after the close$168.60M+2.9%-$3.11$0.79Release
Q2 FY2024ended Jun 30, 2024Jul 30, 2024after the close$178.00M+5.0%$0.39$0.89Release
Q1 FY2024ended Mar 31, 2024May 7, 2024after the close$167.10M+4.2%$0.19$0.62Release
Q4 FY2023ended Dec 31, 2023Feb 29, 2024before the open$181.20M+5.3%$0.50$0.89Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Pacira BioSciences's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Total revenueFY2026$735.00M – $760.00M$745.00M – $770.00MRaisedAug 4, 2026
Total revenueFY2026$745.00M – $770.00M–NewFeb 26, 2026
Gross marginGAAPFY202676% – 78%76% – 78%ReaffirmedAug 4, 2026
Gross marginGAAPFY202676% – 78%–NewFeb 26, 2026
Non-GAAP gross marginnon-GAAPFY202677% – 79%77% – 79%ReaffirmedAug 4, 2026
Non-GAAP gross marginnon-GAAPFY202677% – 79%–NewFeb 26, 2026
EXPAREL net product salesFY2026$600.00M – $620.00M–NewApr 30, 2026
EXPAREL net product salesFY2026$600.00M – $620.00M–NewFeb 26, 2026
Non-GAAP R&D expensenon-GAAPFY2026$105.00M – $115.00M$105.00M – $115.00MLoweredAug 4, 2026
Non-GAAP R&D expensenon-GAAPFY2026$105.00M – $115.00M–NewFeb 26, 2026
Non-GAAP SG&A expensenon-GAAPFY2026$310.00M – $330.00M$320.00M – $340.00MRaisedAug 4, 2026
Non-GAAP SG&A expensenon-GAAPFY2026$320.00M – $340.00M–RaisedFeb 26, 2026
Research and development expenseGAAPFY2026$115.00M – $128.00M$116.00M – $128.00MLoweredAug 4, 2026
Research and development expenseGAAPFY2026$116.00M – $128.00M–NewFeb 26, 2026
Selling, general and administrative expenseGAAPFY2026$349.00M – $376.00M$359.00M – $386.00MRaisedAug 4, 2026
Selling, general and administrative expenseGAAPFY2026$359.00M – $386.00M–RaisedFeb 26, 2026
Stock-based compensationFY2026$54.00M – $59.00M$54.00M – $62.00MLoweredAug 4, 2026
Stock-based compensationFY2026$54.00M – $62.00M–LoweredFeb 26, 2026

Guidance vs results

The last range Pacira BioSciences gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$725.00M – $735.00M$726.40MΣ4QWithin range

Guidance history

Every forecast Pacira BioSciences put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 4, 2026Non-GAAP gross marginFY202677% – 79%Reaffirmed
Aug 4, 2026Gross marginFY202676% – 78%Reaffirmed
Aug 4, 2026Research and development expenseFY2026$115.00M – $128.00MLowered
Aug 4, 2026Selling, general and administrative expenseFY2026$349.00M – $376.00MRaised
Aug 4, 2026Non-GAAP SG&A expenseFY2026$310.00M – $330.00MRaised
Aug 4, 2026Non-GAAP R&D expenseFY2026$105.00M – $115.00MLowered
Aug 4, 2026Stock-based compensationFY2026$54.00M – $59.00MLowered
Aug 4, 2026Total revenueFY2026$735.00M – $760.00MRaised
Aug 4, 2026EXPAREL net product salesFY2026$600.00M – $620.00MLowered
Apr 30, 2026Gross marginFY202676% – 78%New
Apr 30, 2026Non-GAAP gross marginFY202677% – 79%New
Apr 30, 2026EXPAREL net product salesFY2026$600.00M – $620.00MNew
Apr 30, 2026Stock-based compensationFY2026$54.00M – $62.00MLowered
Apr 30, 2026Research and development expenseFY2026$116.00M – $128.00MNew
Apr 30, 2026Selling, general and administrative expenseFY2026$359.00M – $386.00MRaised
Apr 30, 2026Non-GAAP R&D expenseFY2026$105.00M – $115.00MNew
Apr 30, 2026Non-GAAP SG&A expenseFY2026$320.00M – $340.00MRaised
Apr 30, 2026Total revenueFY2026$745.00M – $770.00MNew
Feb 26, 2026Gross marginFY202676% – 78%New
Feb 26, 2026Non-GAAP gross marginFY202677% – 79%New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Pacira BioSciences filed with the SEC as exhibits to Form 8-K or 6-K

  1. Update
  2. Update
  3. Results
  4. Update
  5. News
  6. Results
  7. Results
  8. Update
  9. Results
  10. Results
  11. Results
  12. Update
  13. Results
  14. Update
  15. Results

See a number that looks wrong?